IGFLR1 Specific Neutra™ Antibody Products

Insulin Growth Factor-Like Receptor 1 (IGFLR1) is part of the insulin-like growth factor (IGF) family, an evolutionarily conserved system integral to various cellular processes such as growth, development, and metabolism. The essential elements of the IGF system are depicted in Fig.1. IGFLR1 mediates the effects of IGF and related molecules, impacting a range of physiological functions through distinct signaling pathways. Ongoing research aims to elucidate the specific roles of IGFLR1 and explore its potential as a therapeutic target.

Its Gene ID: 79713, UniProtKB ID: Q9H665, and OMIM ID: 614143.

Fig.1 The IGF system.^{1, 3}

IGFLR1 Signaling Pathway

IGFLR1 signaling is an essential element of the IGF system, governing growth, development, and metabolic functions. When IGFLR1 binds its ligands, it activates intracellular signaling cascades that influence various cellular functions. The primary downstream pathways of IGFL1R are mediated by IR substrates-1 to -4 and Src-homology collagen protein (Shc) isoforms acting as adapter molecules. Phosphorylation of IRS molecules activates the phosphoinositide 3-kinase (PI3K)/Akt pathway, while Shc activation triggers the Ras/Raf/MEK/Erk pathway. These pathways have pleiotropic effects, controlling cell proliferation, differentiation, migration, and the regulation of apoptosis.

Fig.2 The IGFLR1 signaling pathway.^{2, 3}

IGFL1R Neutralizing Antibodies in Therapies

IGFL1R signaling is pivotal in the progression of many human cancers and has become a promising target for new therapeutic development. Numerous monoclonal antibodies have been designed to target IGFL1R by binding to its extracellular domains, thereby blocking ligand binding. A common feature of these anti-IGFL1R antibodies is their ability to down-regulate the receptor over time by promoting its internalization. This receptor-targeting strategy provides therapeutic benefits by enhancing specificity and minimizing toxicity. Due to the common dysregulation of the IGF signaling pathway in human cancers, which frequently includes autocrine loops with IGF-1 or IGF-2 and/or overexpression of IGFL1R, the IGFL1R represents an appealing target for innovative anti-tumor agents. Anti-cancer strategies targeting the IGF signaling system mainly focus on using neutralizing antibodies to inhibit IGFL1R kinase activity.

Services

Creative Biolabs is committed to advancing medical research, providing high-quality IGFLR1-neutralizing antibodies to researchers and pharmaceutical companies worldwide. Our extensive range of IGFLR1-neutralizing antibodies is designed to block the activity of IGFLR1, thereby inhibiting the pathological processes associated with its overactivation. For more information about our IGFLR1-neutralizing antibodies and how they can benefit your research or therapeutic development projects, please contact us. Our team is ready to assist you with your inquiries and provide detailed information on our products and services.

REFERENCES

1. Venuto, Santina, et al. "IGFBP-6 Network in Chronic Inflammatory Airway Diseases and Lung Tumor Progression." International Journal of Molecular Sciences 24.5 (2023): 4804.
2. Biagetti, Betina, and Rafael Simó. "GH/IGF-1 abnormalities and muscle impairment: From basic research to clinical practice." International journal of molecular sciences 22.1 (2021): 415.
3. Under open access license CC BY 4.0, without modification.